Pharmacokinetics of single-dose oral stavudine in subjects with renal impairment and in subjects requiring hemodialysis

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 8, 2000, Pages 2149-2153

  Grasela, Dennis M ^a   Stoltz, Randall R ^b   Barry, Michael ^c   Bone, Michael ^d   Mangold, Bernhard ^a   O'Grady, Padraig ^a   Raymond, Ralph ^a   Haworth, Stephen J ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b GFI Pharmaceutical Services Inc   (United States)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

STAVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY SURFACE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DOSE CALCULATION; DRUG CLEARANCE; FEMALE; HALF LIFE TIME; HEMODIALYSIS; HUMAN; HYPOTENSION; KIDNEY FAILURE; MALE; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-HIV AGENTS; FEMALE; HUMANS; KIDNEY FAILURE; MALE; MIDDLE AGED; RENAL DIALYSIS; STAVUDINE;

EID: 0033942684     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.8.2149-2153.2000     Document Type: Article

References (13)

1. Cretton, E. M., Z. Zhou, L. B. Kidd, H. M. McClure, S. Kaul, M. J. M. Hitchcock, and J.-P. Sommadossi. 1993. In vitro and in vivo disposition and metabolism of 3″deoxy-2′,3′-didehydrothymidine. Antimicrob. Agents Chemother. 37:1816-1825.
2. Dubois, D., and E. F. Dubois. 1916. A formula to estimate the approximate surface area if height and weight be known. Arch. Intern. Med. 17:863-871.
3. Dudley, M. N., K. K. Graham, S. Kaul, S. Galetko, L. Dunkle, M. Browne, and K. Mayer. 1992. Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex. J. Infect. Dis. 166:480-485.
4. Gibaldi, M., and D. Perrier. 1982. Pharmacokinetics, 2nd ed., p. 409-417. Marcel Dekker, Inc., New York, N.Y.
5. Glassock, R. J., A. H. Cohen, G. Danovitch, and K. P. Parsa. 1990. Human immunodeficiency virus (HIV) infection and the kidney. Ann. Intern. Med. 112:35-49.
6. Horton, C. M., M. N. Dudley, S. Kaul, K. H. Mayer, K. Squires, L. Dunkle, and R. Anderson. 1995. Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advanced AIDS-related complex. Antimicrob. Agents Chemother. 39:2309-2315.
7. Janiszewski, S., D. E. Mulnava, S. Kaul, K. A. Dandekar, and R. H. Barbhaiya. 1992. High-performance liquid Chromatographic determination of 2′,3′-didehydro-3′-deoxythymidine, a new anti-human immunodeficiency virus agent, in human plasma and urine. J. Chromatogr. 577:151-156.
8. Kaul, S., V. Mummanemi, and R. H. Barbhaiya. 1995. Dose proportionality of stavudine in HIV seropositive asymptomatic subjects: application to bioequivalence assessment of various capsule formulations. Biopharm. Drug Dispos. 16:125-136.
9. Kline, M. W., L. M. Dunkle, J. A. Church, J. C. Goldsmith, A. T. Harris, M. E. Federici, M. E. Schultze, L. Woods, D. F. Loewen, S. Kaul, A. Cross, V. L. Rutkiewicz, H. W. Rosenblatt. I. C. Hansen, and W. T. Shearer. 1995. A phase I/I evaluation of stavudine (d4T) in children with human immuno-deficiency virus infection. Pediatrics 96:247-252.
10. Macleod, C. M., E. A. Bartley, and S. K. Paul. 1994. Effect of food on oral absorption of stavudine. J. Clin Pharmacol. 34:1025. (Abstract.)
11. Riegelman, S., and P. Collier. 1980. The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J. Pharmacokinet. Biopharm. 8:509-534.
12. Rowland, M., and T. N. Tozer. 1995. Clinical pharmacokinetics: concepts and applications, 3rd ed., p. 443-462. Williams and Wilkins, Baltimore, Md.
13. Schaad, H. J., B. G. Petty, D. M. Grasela, B. Christofalo, R. Raymond, and M. Stewart. 1997. Pharmacokinetics and safety of a single dose of stavudine (d4T) in patients with severe hepatic impairment. Antimicrob. Agents Chemother. 41:2793-2796.